The Q1 earnings beat is marginal and overshadowed by rising operating losses. The stock will trade on pipeline catalysts: watch for the FDA Type A meeting outcome in Q2 and the Phase 3 APOLLO topline data in Q4 2026, which are the primary value drivers. The $730M cash runway into 2029 removes near-term financing risk.
Price Chart
Executive Summary
Disc Medicine reported Q1 2026 EPS of -$1.65, slightly beating the -$1.73 consensus by 4.6%, but net loss widened to $63.5M from $34.1M a year ago on higher R&D and SG&A costs. The key catalyst is the completed enrollment of the Phase 3 APOLLO trial for bitopertin in EPP, with topline data expected in Q4 2026, which could support an FDA resubmission by mid-2027.
Key Financial Metrics
Key Facts
- Q1 2026 EPS of -$1.65 vs consensus -$1.73 (4.6% beat)
- Net loss widened to $63.5M from $34.1M YoY, driven by higher R&D ($45.9M vs $27.8M) and SG&A ($23.6M vs $12.2M)
- Cash, cash equivalents, and marketable securities of $730.2M, providing runway into 2029
- Phase 3 APOLLO trial of bitopertin in EPP fully enrolled (183 patients); topline data expected Q4 2026
- Type A meeting with FDA scheduled for Q2 2026 to discuss bitopertin CRL response; potential FDA decision by mid-2027
- Updated Phase 2 data for DISC-0974 in MF anemia to be presented at ASCO in June 2026
- Phase 2 data for DISC-3405 in PV and Phase 1b data in SCD expected Q4 2026
Financial Impact
Net loss of $63.5M in Q1 2026 vs $34.1M in Q1 2025; cash burn of ~$61M in the quarter
Risk Factors
- Bitopertin Phase 3 APOLLO trial failure or disappointing topline data in Q4 2026
- FDA Type A meeting could result in additional clinical requirements, delaying bitopertin approval
- Rising operating expenses without near-term revenue could pressure valuation if pipeline milestones slip
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3287684 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | 8-K | $74.14 $69.18 | ▼ −6.69% | ▼ −6.19% | $64.48 (−13.03%) |
Sep 9, 2026 22d ago | Press Release | $74.14 $69.18 | ▼ −6.69% | ▼ −6.19% | $64.48 (−13.03%) |
Sep 3, 2026 28d ago | Insider Cluster | $79.23 $68.92 | ▲ +13.01% | ▲ +11.80% | $64.48 (+18.62%) |
Sep 2, 2026 29d ago | 144 | $79.37 $70.06 | ▼ −11.73% | ▼ −10.58% | $64.48 (−18.76%) |
Aug 27, 2026 5w ago | Insider Cluster | $82.55 $79.37 | ▼ −3.85% | ▼ −4.12% | $64.48 (−21.89%) |
Aug 18, 2026 6w ago | Insider Cluster | $80.32 $82.67 | ▲ +2.93% | ▲ +3.31% | $64.48 (−19.72%) |
Aug 14, 2026 6w ago | Insider Cluster | $80.05 $80.94 | ▲ +1.11% | ▲ +2.30% | $64.48 (−19.45%) |
Jul 30, 2026 9w ago | 8-K | $79.21 $77.44 | ▼ −2.23% | ▼ −5.86% | $64.48 (−18.60%) |
Jul 30, 2026 9w ago | Press Release | $79.21 $77.44 | ▼ −2.23% | ▼ −5.86% | $64.48 (−18.60%) |
Jul 14, 2026 11w ago | Insider Cluster | $76.02 $74.32 | ▼ −2.24% | ▼ −1.26% | $64.48 (−15.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access